i-Lumen Scientific

Clinical-stage US medical-technology company (Bloomington, Minnesota) developing non-invasive bioelectric (microcurrent) stimulation therapy for dry AMD — the i-Lumen AMD System — now in a sham-controlled pivotal trial. Assignee of US12589243B2 (ocular-therapy devices and controller interfaces) catalogued in visual-prosthesis-patents.

Overview

• Therapy: transpalpebral microcurrent stimulation (through the closed eyelid; in-office, no implant), intended to support the retinal pigment epithelium’s transepithelial potential (TEP) and thereby RPE function and retinal electrophysiology in intermediate-to-advanced dry AMD. CEO: John VeLure.
• Clinical: the i-SIGHT2 pivotal study will enrol 120 participants across the UK, Australia, New Zealand and — following FDA IDE approval announced 31 March 2026 — the United States (US enrolment anticipated from late April 2026). First participant treated at London North West University Healthcare NHS Trust (Christiana Dinah); Global PI Prof. Timothy Jackson (King’s College Hospital, London); sham-controlled design (registry NCT06662162). Success is intended to support regulatory submissions for commercialisation.
• IP: granted US12589243B2 covers the wearable periorbital-electrode apparatus and the phosphene-threshold calibration/controller interfaces; the family’s KR member (“Electrode Systems and Methods for Vision Treatment”) also appears in the patent-landscape table on retinal-prosthesis.

Positioning

Adjacent technology — not a visual prosthesis, and not an implant: electrotherapy intended to slow/arrest AMD progression and support retinal function. It occupies the same “treatment layer” as OkuStim TES (see retinal-prosthesis-companies), overlapping the maculopathy patient population addressed by prostheses (retinal-prosthesis) while following a device-therapy regulatory pathway rather than a restorative-implant one.

Caveats

• Company and clinical status per press release and trial registry; efficacy is not yet established (pivotal stage); confidence: medium.

Related pages

• visual-prosthesis-patents — US12589243B2 entry
• retinal-prosthesis — category / patent landscape
• retinal-prosthesis-companies — OkuStim TES therapy comparison (non-implant therapies)

References

• i-Lumen Scientific, Inc. “i-Lumen Scientific Receives FDA Approval of IDE to Initiate U.S. Enrollment in i-SIGHT2 Clinical Study for dry AMD.” PR Newswire, 31 March 2026. https://www.prnewswire.com/news-releases/i-lumen-scientific-receives-fda-approval-of-ide-to-initiate-us-enrollment-in-i-sight2-clinical-study-for-dry-amd-302729117.html
• ClinicalTrials.gov. “Microcurrent Stimulation Therapy for Nonexudative Age-Related Macular Degeneration.” NCT06662162. https://clinicaltrials.gov/study/NCT06662162
• i-Lumen Scientific company site. https://www.i-lumen.com/ (accessed 14 September 2026)